NIH launches 3D Print Exchange for Researchers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

NIH launches 3D Print Exchange for Researchers



The National Institutes of Health has launched the NIH 3D Print Exchange, a public website that enables users to share, download, and edit three-dimensional (3D) print files related to health and science. These files can be used, for example, to print custom laboratory equipment and models of bacteria and human anatomy. The launch coincided with the first White House Maker Faire External, an event designed to celebrate US innovation in science, technology, engineering, and math.

NIH uses 3D printing to study viruses, repair and enhance laboratory apparatus, and help plan medical procedures. The 3D Print Exchange makes these types of files freely available, along with video tutorials for new users and a discussion forum to promote collaboration. The site also features tools that convert scientific and clinical data into ready-to-print 3D files.

The 3D Print Exchange is a collaborative effort led by NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Additional support is provided by other NIH components, including the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Library of Medicine. The 3D Print Exchange is funded in part by the US Department of Health and Human Services through its Ignite External Web Site Policy and Ventures External Web Site Policy programs, which help support innovation within the agency.

Source: National Institutes of Health

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here